

# Xuerong Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3851739/publications.pdf>

Version: 2024-02-01

30  
papers

1,297  
citations

471509

17  
h-index

454955

30  
g-index

33  
all docs

33  
docs citations

33  
times ranked

1969  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sulfonylurea receptor 1-expressing cancer cells induce cancer-associated fibroblasts to promote non-small cell lung cancer progression. <i>Cancer Letters</i> , 2022, 536, 215611.	7.2	11
2	Progress of Breast Cancer basic research in China. <i>International Journal of Biological Sciences</i> , 2021, 17, 2069-2079.	6.4	43
3	BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells. <i>Oncology Reports</i> , 2021, 45, .	2.6	10
4	Trichostatin A downregulates bromodomain and extra-terminal proteins to suppress osimertinib resistant non-small cell lung carcinoma. <i>Cancer Cell International</i> , 2021, 21, 216.	4.1	9
5	The value of circulating tumor cells with positive centromere probe 8 in the diagnosis of small pulmonary nodules. <i>Translational Oncology</i> , 2021, 14, 101052.	3.7	3
6	Tumor-derived exosomal miR-19b-3p facilitates M2 macrophage polarization and exosomal LINC00273 secretion to promote lung adenocarcinoma metastasis via Hippo pathway. <i>Clinical and Translational Medicine</i> , 2021, 11, e478.	4.0	86
7	Role of endothelin receptor type B (EDNRB) in lung adenocarcinoma. <i>Thoracic Cancer</i> , 2020, 11, 1885-1890.	1.9	20
8	p70S6K Promotes Acquired Resistance of Erlotinib Through Induction of Epithelial-Mesenchymal Transition in Non-Small Cell Lung Carcinoma. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5257-5270.	2.0	4
9	AEG-1 promotes the growth of gastric cancer through the upregulation of eIF4E expression. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5887-5895.	2.0	3
10	Glibenclamide Targets Sulfonylurea Receptor 1 to Inhibit p70S6K Activity and Upregulate KLF4 Expression to Suppress Non-Small Cell Lung Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2085-2096.	4.1	19
11	Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression. <i>Cancer Biology and Therapy</i> , 2018, 19, 407-415.	3.4	36
12	Inhibition of p70S6K does not mimic the enhancement of Akt phosphorylation by rapamycin. <i>Heliyon</i> , 2017, 3, e00378.	3.2	11
13	AEG-1 induces gastric cancer metastasis by upregulation of eIF4E expression. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 3481-3493.	3.6	15
14	AEG-1/MTDH-activated autophagy enhances human malignant glioma susceptibility to TGF- $\beta$ 1-triggered epithelial-mesenchymal transition. <i>Oncotarget</i> , 2016, 7, 13122-13138.	1.8	40
15	p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 36539-36550.	1.8	39
16	Oncogenic miR-9 is a target of erlotinib in NSCLCs. <i>Scientific Reports</i> , 2015, 5, 17031.	3.3	54
17	Oroxilin A induces autophagy in human malignant glioma cells via the mTOR-STAT3-Notch signaling pathway. <i>Molecular Carcinogenesis</i> , 2015, 54, 1363-1375.	2.7	46
18	EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer. <i>PLoS ONE</i> , 2015, 10, e0125402.	2.5	72

#	ARTICLE	IF	CITATIONS
19	GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. <i>Oncotarget</i> , 2015, 6, 8974-8987.	1.8	15
20	AEG-1 Is a Target of Perifosine and Is Over-Expressed in Gastric Dysplasia and Cancers. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2873-2880.	2.3	24
21	MicroRNA-27a inhibitors alone or in combination with perifosine suppress the growth of gastric cancer cells. <i>Molecular Medicine Reports</i> , 2013, 7, 642-648.	2.4	10
22	Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth. <i>Oncology Reports</i> , 2013, 29, 2422-2430.	2.6	36
23	Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3 $\beta$ in NSCLC cells. <i>Cancer Biology and Therapy</i> , 2012, 13, 1009-1017.	3.4	14
24	Downregulation of IRS-1 promotes metastasis of head and neck squamous cell carcinoma. <i>Oncology Reports</i> , 2012, 28, 659-667.	2.6	22
25	Enhancing mTOR-targeted cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 1193-1203.	3.4	56
26	Perifosine Inhibits Mammalian Target of Rapamycin Signaling through Facilitating Degradation of Major Components in the mTOR Axis and Induces Autophagy. <i>Cancer Research</i> , 2009, 69, 8967-8976.	0.9	137
27	Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors's anticancer efficacy. <i>Cancer Biology and Therapy</i> , 2008, 7, 1952-1958.	3.4	86
28	Enhancing Mammalian Target of Rapamycin (mTOR)-Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt Activation. <i>Cancer Research</i> , 2008, 68, 7409-7418.	0.9	152
29	Inhibition of Mammalian Target of Rapamycin Induces Phosphatidylinositol 3-Kinase-Dependent and Mnk-Mediated Eukaryotic Translation Initiation Factor 4E Phosphorylation. <i>Molecular and Cellular Biology</i> , 2007, 27, 7405-7413.	2.3	137
30	The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2029-2038.	4.1	87